| 梁启廉,张英,赖振南,等.同步放化疗对非小细胞肺癌患者Fas水平的影响[J].中华放射医学与防护杂志,2008,28(6):628-631.LIANG Qi-lian,ZHANG Ying,LAI Zhen-nan,et al.The level change of serum soluble Fas for non-small cell lung cancer patients with concurrent radio-chemotherapy[J].Chin J Radiol Med Prot,2008,28(6):628-631 |
| 同步放化疗对非小细胞肺癌患者Fas水平的影响 |
| The level change of serum soluble Fas for non-small cell lung cancer patients with concurrent radio-chemotherapy |
| 投稿时间：2007-12-10 |
| DOI： |
| 中文关键词: 肺肿瘤/放化疗法 血清可溶性Fas 酶联免疫吸附试验 |
| 英文关键词:Lung neoplasms/radio-chemotherapy Serum soluble Fas Enzyme linked immunosorbent assays |
| 基金项目:广东省医学科研课题基金资助项目(B1999138) |
|
| 摘要点击次数: 3412 |
| 全文下载次数: 2304 |
| 中文摘要: |
| 目的 用酶联免疫吸附试验研究非小细胞肺癌患者同步放化疗对血清可溶性Fas的影响及其与预后的关系。方法 对60例患者比较治疗前、治疗后1个月血清Fas水平变化,并设正常对照组。比较治疗有效组(完全缓解+部分缓解,50例)与无效组(无变化+进展,10例) 治疗前Fas水平变化。以2年生存为观察指标,观察血清Fas水平对生存时间的影响。结果 非小细胞肺癌患者治疗前血清Fas水平明显高于正常对照组(8.55±0.63) ng/L和(6.03±0.55) ng/L(t=18.63,P<0.01),治疗后1个月明显低于治疗前(7.24±0.52) ng/L和(8.55±0.63) ng/L(t=12.44,P<0.01)。治疗有效组疗前血清Fas水平明显低于无效组的(8.02±0.43)ng/L和(8.97±0.42)ng/L(t=8.67,P<0.01)。生存满2年者(26例)治疗前Fas水平明显低于生存不足2年者(34例)(t=645.88,P<0.05)。结论 同步放化疗可降低非小细胞肺癌患者血清可溶性Fas水平,治疗前后Fas水平变化有可能成为判断非小细胞肺癌患者预后的观察指标。 |
| 英文摘要: |
| Objective Study on the change of serum soluble Fas (sFas) level and prognostic relation for non-small cell lung cancer(NSCLC) patients with concurrent radio-chemotherapy using enzyme linked immunosorbent assays(ELISA).Methods Sixty patients were obtained. The sFas level were compared before treatment with one month after treatment, and healthy donors were used as controls level of sFas. The sFas level of before treatment were compared treatment efficiency patients(complete remission and partial remission, 50 patients) and treatment inefficiency patients(no change and progressive disease, 10 patients). The correlation was analyzed between 2-year survival NSCLC patients and their sFas level.Results The sFas level before treatment in NSCLC patients was obviously higher than healthy controls (8.55±0.63) ng/L and (6.03±0.55) ng/L; (t=18.63,P<0.01), with 1 month after treatment obviously lower than before treatment in NSCLC patients (7.24±0.52) ng/L and (8.55±0.63) ng/L;(t=12.44,P<0.01). The sFas level of before treatment was treatment efficiency patients obviously lower than treatment ineffectived patients (8.02±0.43)ng/L and (8.97±0.42)ng/L; (t=8.67,P<0.01),with 2-year survival patients obviously(26 patients)lower than shortage 2-year survival patients(34 patients)(t=645.88,P<0.05).Conclusions Concurrent radio-chemotherapy can reduce sFas level in NSCLC patients, the changes of sFas level before and after treatment may provide worth prognostic for NSCLC patients. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|